Economic modeling and sensitivity analysis

Area of Science:

• Pharmacoeconomics
• Health Economics
• Health Services Research

Background:

• Concerns regarding research credibility and bias in pharmacoeconomics (PE).
• Issues include irreproducibility, inappropriate data use, lack of transparency, and difficulty comparing studies.
• Skepticism about the validity, reliability, and relevance of PE studies for healthcare decision-makers.

Purpose of the Study:

• To propose reporting standards to enhance the credibility of pharmacoeconomics research.
• To address concerns about transparency and comparability in economic modeling.
• To improve the acceptance and application of PE findings by policymakers.

Main Methods:

• Utilized a case study in lipid pharmacoeconomics.
• Proposed two general reporting standards for PE research.
• Recommended either software distribution for PE models or multivariate sensitivity analysis.

Main Results:

• Software distribution allows validation and adaptation of PE models.
• Multivariate sensitivity analysis enables consistent and comparable results across studies.
• Implementation of these standards can increase trust in PE findings.

Conclusions:

• Adoption of standardized reporting, including software sharing or sensitivity analysis, is crucial for PE credibility.
• Mandating these guidelines in scientific journals and by healthcare decision-makers will foster wider acceptance.
• Standardization will establish pharmacoeconomics as a practical, real-world science.